Palacio de Congresos de Granada
Paseo del Violón S/N
18006 Granada, Spain
Tel +34 958 246 700 Fax +34 958 246 702
http://www.pcgr.org/

Hotel Andalucia Center
Avenida América S/N
18006 Granada, Spain
Tel +34 958 205 000 Fax +34 958 289 696
http://www.hotelescenter.com

Hotel Saray
C/ Profesor Tierno Galvan 4
18006 Granada, Spain
Tel +34 958 130 009 Fax +34 958 129 161
http://www.hotel-saray.com/

Senator Granada Spa Hotel
Paseo Violón S/N
18005 Granada, Spain
Tel +34 958 131 000 Fax +34 958 131 088
http://senator.hotelsearch.com/granadaspa/

Hotel Carmen
Acera del Darro 62
18005 Granada, Spain
Tel +34 95 825 83 00 Fax +34 95 825 64 62
http://www.hotelmorconcien.com/

Hotel San Anton
C/ San Anton, 74
18005 Granada, Spain
Tel +34 958 520 100 Fax +34 958 521 945
http://www.hotelsanantongranada.com/

Hotel Villa Oniria
C/ San Antón 28
18005 Granada, Spain
Tel +34 956 535 358
http://www.villaoniria.com/

Hotel Melia Granada
C/ Ángel Ganivet 7
18009 Granada, Spain
Tel +34 958 227 400 Fax +34 958 227 403
http://es.selmelia.com/hotel/melia-granada.htm

Hotel NH Victoria
C/ Puerta Real 3
18005 Granada, Spain
Tel +34 958 536 216 Fax +34 95.826.6560
http://www.nh-hoteles.es/

Hotel Hesperia Granada
Plaza Gamboa S/N
18009 Granada, Spain
Tel +34 958 018 400 Fax +34 958 018 410
http://www.hesperia-granada.com

Tryp Albayzin
Carrera Genil 48
18005 Granada, Spain
Tel +34 958 220 002 Fax +34 958 220 181
http://es.selmelia.com/hotel/tryp-albayzin.htm
6th Annual ENETS Conference
for the

Diagnosis and Treatment of Neuroendocrine Tumor Disease

5 - 7 March 2009
Granada • Spain

Granada Congress & Exhibition Centre

Supported by Novartis Pharmaceutical Corporation and Ipsen Beaufour
The ENETS Executive Committee extends a warm welcome to its 6th Annual Conference in Granada, Spain. In attending this meeting, you join some of the most respected and dynamic researchers and key opinion leaders in the field of neuroendocrine tumor research. Over the next two days, they will be detailing the most relevant and significant advances in the field today. Our aim is to give you beneficial lessons to help you in your daily clinical practice.

On behalf of the scientific organizing committee, I welcome you to Granada. The city is a highly appropriate place to hold our conference: its legacy of blended cultures mirrors our Society’s mission in fostering international cooperation toward solving the complex clinical problems neuroendocrine tumors present. The Society today claims more than 550 members, hailing from 48 countries – this is a proud achievement for a research society dedicated to a rare disease, and one founded only five years ago. Again, I welcome all participants to our annual meeting and appreciate the distances traveled to be here.

Our 2008 conference in Paris received very positive reviews and we hope that the Granada meeting will be just as rewarding. In inviting the conference lecturers, we hope to exhibit the Society’s work of this past year, including the ENETS Guidelines for the Standards of Care. But we also felt it important to add some new aspects to the program. This would encompass poorly differentiated endocrine carcinomas, novel approaches to NET treatment, and a session on combined therapy and clinical trials. We also have expanded the program to include an additional session for clinical research abstracts.

I am exceptionally proud to announce that we received 119 abstracts for the meeting. The growth in NET research, as well as the continued increase in membership registrations and abstract submissions, speaks for itself and our future work in the field.

The ENETS Annual Conference this year is sponsored by the pharmaceutical firms Novartis, as platinum sponsor, and Ipsen, as silver sponsor. I would like to take this opportunity to thank both for their continued support for and interest in ENETS. I would also like to thank the companies CISBIO, Covidien, ITG Isotope Technologies Garching and Sirtex, which are exhibiting during the conference. I welcome each of you to Granada and to the ENETS 6th Annual Conference.

Guido Rindi, M.D., Ph.D.
Parma, Italy
Chairman, European Neuroendocrine Tumor Society (ENETS)
Saturday, 7 March 2009

08:30 - 09:30 SESSION 5: Liver Metastases
Chairs: D. O'Toole, Dublin, IRL
        D. J. Kwekkeboom, Rotterdam, NED
08:30 - 08:50 Key Players in Metastases Development
        D. R. Welch, Birmingham, AL, USA
08:50 - 09:10 Surgery and Ablation
        T. Steinmüller, Berlin, GER
09:10 - 09:30 Medical Treatment
        K. Öberg, Uppsala, SWE

09:30 - 10:15 SELECTED ABSTRACTS (III): Basic/Translational Research
Chairs: M. Caplin, London, GBR
        U.-F. Pape, Berlin, GER
09:30 - 09:45 Molecular predictors of response to chemotherapy in
        advanced/metastatic gastroenteropancreatic endocrine tumors
        A. Couvelard, Clichy, FRA
09:45 - 10:00 Adenosine A2 receptor signalling mediates chromogranin A
        secretion from neuroendocrine tumors
        A. Kalhan, Cardiff, GBR
10:00 - 10:15 Dual expression of alpha-internexin in pancreatic endocrine tumors
        and its implications
        M. Mei, Beijing, CHN

10:15 - 10:45 COFFEE BREAK
10:45 - 11:00 Young Investigator Awards
        G. Kaltsas, Athens, GRE
        G. Rindi, Parma, ITA

11:00 - 11:30 SESSION 6: Combined Therapy and Clinical Trials
Chairs: B. Kos-Kudłaszewska, Zabrze, POL
        M. Kulke, Boston, MA, USA
11:00 - 11:30 Hot-Off-the-Press Results of Ongoing Trials in the EU and the USA
        C. Lombard-Bohas, Lyon, FRA
        J. Yao, Houston, TX, USA
11:30 - 12:00 Single or Monotherapy: Need for Combinations?
        L. Kvols, Tampa, FL, USA
12:00 - 12:30 Basic Evidence for Future Trials
        E. Van Cutsem, Leuven, BEL
12:30 - 12:50 Lessons from Granada
        R. Jensen, Bethesda, MD, USA
12:50 - 13:00 Concluding Remarks
        G. Rindi, Parma, ITA

END OF MEETING

Mark Your Calendars Now!

7th Annual ENETS Conference
for the Diagnosis and Treatment
of Neuroendocrine Tumors
For more information, visit:
www.neuroendocrine.net
11 - 13 March 2010 • Berlin • Germany
Conference organization:
ENETS Coordinating Office
c/o Charité - University Hospital
campus Virchow-Klinikum
Hepatology and Gastroenterology
Augustenburger Platz 1
13353 Berlin, Germany
tel +49 (0)30 450-553 096/-553 042
fax +49 (0)30 450-553 942
www.neuroendocrine.net
office@neuroendocrine.net

Scientific organizing committee:
Martyn Caplin London GBR
Wouter de Herder Rotterdam NED
Barbro Eriksson Uppsala SWE
Dermot O'Toole Dublin IRL
Guido Rindi Parma ITA
Philippe Ruszniewski Clichy FRA
Bertram Wiedenmann Berlin GER
Friday, 6 March 2009

08:30 - 10:30 SESSION 2: Various localizations, various problems
Chairs: W. de Herder, Rotterdam, NED
        G. Delle Fave, Rome, ITA

08:30 - 09:00 Lung
        E. Baudin, Villejuif, FRA

09:00 - 09:30 Pancreas
        M. Mallath, Mumbai, IND

09:30 - 10:00 Rectum
        J. Ramage, Basingstoke, GBR

10:00 - 10:30 Ileum
        F. Costa, Sao Paulo, BRA

10:30 - 11:00 ENETS Life Achievement Award
Chair: G. Rindi, Parma, ITA
Recipient: R. Arnold, Marburg/Munich, GER
Dedication: B. Wiedenmann, Berlin, GER

11:00 - 11:30 COFFEE BREAK

11:30 - 12:30 SESSION 3: Poorly Differentiated Endocrine Carcinomas
Chairs: L. Kvols, Tampa, FL, USA; P. Komminoth, Zurich, SUI

11:30 - 11:50 Diagnosis
        O. Nilsson, Gothenborg, SWE

11:50 - 12:10 Therapy and Management (I): Surgery
        H. Ahlman, Gothenborg, SWE

12:10 - 12:30 Therapy and Management (II): Medical Treatment
        J. Yao, Houston, TX, USA

12:30 - 14:00 LUNCH

14:00 - 15:15 SELECTED ABSTRACTS (II): Clinical Research
Chairs: R. V. Thakker, Oxford, GBR
        D. Ferone, Genoa, ITA

14:00 - 14:15 Prevalence and features of MEN1 in a large cohort of gastroentero-
pancreatic and thoracic NET: data from a large multicentric Italian
database
        P. Ferolla, Perugia, ITA

14:15 - 14:30 Clinical results of PRRT with 90Y-DOTATATE and 90Y/177Lu-
DOTATATE - what is better for therapy?
        L. Krolicki, Warsaw, POL

14:30 - 14:45 Chemotherapy with 5-Fluorouracil, cisplatin and streptozocin
(FCiSt) for neuroendocrine tumors
        T. Meyer, London, GBR

14:45 - 15:00 Placebo-controlled, double-blind, prospective, randomized study on
the effect of Octreotide LAR in the control of tumor growth in patients
with metastatic neuroendocrine midgut tumors: a report from the
PROMID Study Group
        A. Rinke, Marburg, GER

15:00 - 15:15 First line treatment of metastatic pancreatic endocrine carcinomas
with capecitabine and temozolomide
        J. Strosberg, Tampa, FL, USA

15:15 - 16:15 SESSION 4: Surgery, Established Techniques and Novel Approaches
Chairs: R. Kianmanesh, Colombes, FRA
        B. Eriksson, Uppsala, SWE

15:15 - 15:35 Lung
        E. Lim, London, GBR

15:35 - 15:55 Gut
        I. Modlin, New Haven, CT, USA

15:55 - 16:15 Pancreas
        A. Sauvanet, Clichy, FRA

16:15 - 17:00 Poster Viewing

17:00 SATELLITE SYMPOSIA
## SESSION PARTICIPANTS

<table>
<thead>
<tr>
<th>Name</th>
<th>City</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>H. Ahlman</td>
<td>Gothenborg</td>
<td>SWE</td>
</tr>
<tr>
<td>G. Åkerström</td>
<td>Gothenborg</td>
<td>SWE</td>
</tr>
<tr>
<td>R. Arnold</td>
<td>Munich</td>
<td>GER</td>
</tr>
<tr>
<td>E. Baudin</td>
<td>Villejuif</td>
<td>FRA</td>
</tr>
<tr>
<td>M. Caplin</td>
<td>London</td>
<td>GBR</td>
</tr>
<tr>
<td>F. Costa</td>
<td>São Paulo</td>
<td>BRA</td>
</tr>
<tr>
<td>W. de Herder</td>
<td>Rotterdam</td>
<td>NED</td>
</tr>
<tr>
<td>G. Delle Fave</td>
<td>Rome</td>
<td>ITA</td>
</tr>
<tr>
<td>B. Eriksson</td>
<td>Uppsala</td>
<td>SWE</td>
</tr>
<tr>
<td>D. Ferone</td>
<td>Genoa</td>
<td>ITA</td>
</tr>
<tr>
<td>A. Grossman</td>
<td>London</td>
<td>GBR</td>
</tr>
<tr>
<td>R. Jensen</td>
<td>Bethesda, MD</td>
<td>USA</td>
</tr>
<tr>
<td>G. Delle Fave</td>
<td>Rome</td>
<td>ITA</td>
</tr>
<tr>
<td>B. Kos-Kudłaa</td>
<td>Zabrze</td>
<td>POL</td>
</tr>
<tr>
<td>M. Kulke</td>
<td>Boston, MA</td>
<td>USA</td>
</tr>
<tr>
<td>L. Kvols</td>
<td>Tampa, FL</td>
<td>USA</td>
</tr>
<tr>
<td>D. Kwekkeboom</td>
<td>Rotterdam</td>
<td>NED</td>
</tr>
<tr>
<td>E. Lim</td>
<td>London</td>
<td>GBR</td>
</tr>
<tr>
<td>C. Lombard-Bohas</td>
<td>Lyon</td>
<td>FRA</td>
</tr>
<tr>
<td>M. Mallath</td>
<td>Mumbai</td>
<td>IND</td>
</tr>
<tr>
<td>I. Modlin</td>
<td>New Haven, CT</td>
<td>USA</td>
</tr>
<tr>
<td>O. Nilsson</td>
<td>Gothenborg</td>
<td>SWE</td>
</tr>
<tr>
<td>K. Öberg</td>
<td>Uppsala</td>
<td>SWE</td>
</tr>
<tr>
<td>D. O’Toole</td>
<td>Dublin</td>
<td>IRL</td>
</tr>
<tr>
<td>U.-F. Pape</td>
<td>Berlin</td>
<td>GER</td>
</tr>
<tr>
<td>U. Plöckinger</td>
<td>Berlin</td>
<td>GER</td>
</tr>
<tr>
<td>J. Ramage</td>
<td>Basingstoke</td>
<td>GBR</td>
</tr>
<tr>
<td>G. Rindi</td>
<td>Parma</td>
<td>ITA</td>
</tr>
<tr>
<td>P. Ruszniewski</td>
<td>Clichy</td>
<td>FRA</td>
</tr>
<tr>
<td>H. Sasano</td>
<td>Sendai</td>
<td>JAP</td>
</tr>
<tr>
<td>A. Sauvanet</td>
<td>Clichy</td>
<td>FRA</td>
</tr>
<tr>
<td>T. Steinmüller</td>
<td>Berlin</td>
<td>GER</td>
</tr>
<tr>
<td>R. V. Thakker</td>
<td>Oxford</td>
<td>GBR</td>
</tr>
<tr>
<td>E. Van Cutsem</td>
<td>Leuven</td>
<td>BEL</td>
</tr>
<tr>
<td>B. Wiedenmann</td>
<td>Berlin</td>
<td>GER</td>
</tr>
<tr>
<td>J. Yao</td>
<td>Houston, TX</td>
<td>USA</td>
</tr>
</tbody>
</table>

## ABSTRACT PRESENTERS

<table>
<thead>
<tr>
<th>Name</th>
<th>City</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>J. Ardill</td>
<td>Belfast</td>
<td>GBR</td>
</tr>
<tr>
<td>A. Astudillo</td>
<td>Oviedo</td>
<td>ESP</td>
</tr>
<tr>
<td>R. Bettini</td>
<td>Verona</td>
<td>ITA</td>
</tr>
<tr>
<td>P. Brown</td>
<td>The Woodlands, TX</td>
<td>USA</td>
</tr>
<tr>
<td>A. Couvelard</td>
<td>Clichy</td>
<td>FRA</td>
</tr>
<tr>
<td>A. Falchetti</td>
<td>Florence</td>
<td>ITA</td>
</tr>
<tr>
<td>P. Ferolla</td>
<td>Perugia</td>
<td>ITA</td>
</tr>
<tr>
<td>A. Kalhan</td>
<td>Cardiff</td>
<td>GBR</td>
</tr>
<tr>
<td>L. Krolicki</td>
<td>Warsaw</td>
<td>POL</td>
</tr>
<tr>
<td>M. Mei</td>
<td>Beijing</td>
<td>CHN</td>
</tr>
<tr>
<td>T. Meyer</td>
<td>London</td>
<td>GBR</td>
</tr>
<tr>
<td>A. Rinke</td>
<td>Marburg</td>
<td>GER</td>
</tr>
<tr>
<td>J. Strosberg</td>
<td>Tampa, FL</td>
<td>USA</td>
</tr>
</tbody>
</table>
Thursday, 5 March 2009

11:00 - 13:00 REGISTRATION

13:00 - 13:20 Welcome and Introduction
   G. Rindi, ENETS Chairman, Parma, ITA

13:20 - 14:30 SESSION 1: Standards of Care
   Chairs: U. Plöckinger, Berlin, GER
          A. Grossman, London, GBR

   U. Plöckinger, Berlin, GER

   13:35 - 13:55 Diagnosis
   B. Eriksson, Uppsala, SWE

   13:55 - 14:15 Medical Therapy
   P. Ruszniewski, Clichy, FRA

   14:15 - 14:30 Surgical Therapy
   G. Åkerström, Gothenborg, SWE

14:30 - 15:00 COFFEE BREAK

15:00 - 16:15 Selected Abstracts (I): Clinical Research
   Chairs: G. Kaltsas, Athens, GRE
          H. Sasano, Sendai, JAP

   15:00 - 15:15 Assessment of the sensitivity of circulating neurokinin A and chromogranin A to changing prognosis in patients with serotonin-producing endocrine tumors of the ileum and colon
   J. Ardill, Belfast, GBR

   15:15 - 15:30 Snail as epithelial-mesenchymal transition marker in neuroendocrine tumors of the lung
   A. Astudillo, Oviedo, ESP

   15:30 - 15:45 Non-functioning pancreatic endocrine tumors: Any correlation of tumor size with malignancy?
   R. Bettini, Verona, ITA

   15:45 - 16:00 LX1032: A novel approach for managing gastrointestinal symptoms in carcinoid syndrome
   P. Brown, The Woodlands, TX, USA

   16:00 - 16:15 Early identification of the MEN1-associated gastrinomas: Use of the secretin test in the experience of the Center for Hereditary Endocrine Tumors of Florence, Italy
   A. Falchetti, Florence, ITA

16:15 - 17:15 Poster Viewing

17:15 - 18:15 ENETS General Assembly

18:15 WELCOME RECEPTION